Literature DB >> 33398663

Effective Data Sharing as a Conduit for Advancing Medical Product Development.

Stephen R Karpen1, J Kael White1, Ariana P Mullin1, Inish O'Doherty1, Lynn D Hudson1, Klaus Romero1, Sudhir Sivakumaran1, Diane Stephenson1, Emily C Turner1, Jane Larkindale2.   

Abstract

INTRODUCTION: Patient-level data sharing has the potential to significantly impact the lives of patients by optimizing and improving the medical product development process. In the product development setting, successful data sharing is defined as data sharing that is actionable and facilitates decision making during the development and review of medical products. This often occurs through the creation of new product development tools or methodologies, such as novel clinical trial design and enrichment strategies, predictive pre-clinical and clinical models, clinical trial simulation tools, biomarkers, and clinical outcomes assessments, and more.
METHODS: To be successful, extensive partnerships must be established between all relevant stakeholders, including industry, academia, research institutes and societies, patient-advocacy groups, and governmental agencies, and a neutral third-party convening organization that can provide a pre-competitive space for data sharing to occur.
CONCLUSIONS: Data sharing focused on identified regulatory deliverables that improve the medical product development process encounters significant challenges that are not seen with data sharing aimed at advancing clinical decision making and requires the commitment of all stakeholders. Regulatory data sharing challenges and solutions, as well as multiple examples of previous successful data sharing initiatives are presented and discussed in the context of medical product development.

Entities:  

Keywords:  Data; Data-sharing; Drug development tools; Product development; Public–private partnerships; Regulatory science

Mesh:

Year:  2021        PMID: 33398663      PMCID: PMC7780909          DOI: 10.1007/s43441-020-00255-8

Source DB:  PubMed          Journal:  Ther Innov Regul Sci        ISSN: 2168-4790            Impact factor:   1.778


  3 in total

1.  Innovations in Therapy Development for Rare Diseases Through the Rare Disease Cures Accelerator-Data and Analytics Platform.

Authors:  Jane Larkindale; Alexandre Betourne; Amanda Borens; Vanessa Boulanger; Vickie Theurer Crider; Pamela Gavin; Jackson Burton; Richard Liwski; Klaus Romero; Ramona Walls; Jeffrey S Barrett
Journal:  Ther Innov Regul Sci       Date:  2022-06-06       Impact factor: 1.337

Review 2.  Recommendations to Optimize the Use of Volumetric MRI in Huntington's Disease Clinical Trials.

Authors:  Kirsi M Kinnunen; Ariana P Mullin; Dorian Pustina; Emily C Turner; Jackson Burton; Mark F Gordon; Rachael I Scahill; Emily C Gantman; Simon Noble; Klaus Romero; Nellie Georgiou-Karistianis; Adam J Schwarz
Journal:  Front Neurol       Date:  2021-10-22       Impact factor: 4.003

3.  Licensing of Orphan Medicinal Products-Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021.

Authors:  Frauke Naumann-Winter; Franziska Wolter; Ulrike Hermes; Eva Malikova; Nils Lilienthal; Tania Meier; Maria Elisabeth Kalland; Armando Magrelli
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.